Kepler Capital analyst Jon Berggren maintained a Buy rating on Calliditas Therapeutics (CALT – Research Report) on August 19 and set a price target of SEK140.00. The company’s shares closed last Friday at $16.13.
According to TipRanks, Berggren is ranked #7309 out of 7973 analysts.
Currently, the analyst consensus on Calliditas Therapeutics is a Moderate Buy with an average price target of $20.78.
See today’s best-performing stocks on TipRanks >>
CALT market cap is currently $477.7M and has a P/E ratio of -6.44.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Calliditas Therapeutics AB operates as a specialty pharmaceutical company in Sweden. The company is engaged in the provision of pharmaceutical products for patients with niche indications. It is focused on the development and commercialization of the product candidate Nefecon intended for the treatment of patients with the inflammatory renal disease IgA nephropathy, a disease that causes chronic inflammation of the kidneys.
Read More on CALT:
- IHS Holding (IHS) Gets a Buy from J.P. Morgan
- GME vs. BBBY: Which Meme Stock is Less Risky?
- Maxim Group Keeps Their Buy Rating on VirTra (VTSI)
- Maxim Group Sticks to Their Buy Rating for ATAI Life Sciences (ATAI)
- Analysts Offer Insights on Technology Companies: AmpliTech Group (AMPG) and Society Pass (SOPA)